Dexcel Pharma Technologies Ltd. 13D and 13G filings for Roivant Sciences Ltd.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 06:51 am Unchanged |
2023-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% |
0 (Unchanged) |
Filing |
| 2023-02-14 4:08 pm Purchase |
2022-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% |
4,040,285 (+4.09%) |
Filing |
| 2022-02-10 4:26 pm Purchase |
2021-12-31 | 13G | Roivant Sciences Ltd. ROIV |
Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% |
98,809,158 (New Position) |
Filing |